MedTrace Logo

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

NCT05741359 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-11-25

No results posted yet for this study

Summary

This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.

Conditions

  • Non-hodgkin Lymphoma,B Cell

Interventions

DRUG

CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection

CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Bioray Laboratories

    lead INDUSTRY

Principal Investigators

  • Wei Li · Bioray Laboratories

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2026-11-20
Completion
2027-01-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05741359 on ClinicalTrials.gov